Cronos Group Inc.

NasdaqGM:CRON Voorraadrapport

Marktkapitalisatie: US$987.9m

Cronos Group Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Cronos Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 58.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 9.7%. De inkomsten zijn gegroeid met een gemiddelde van 18.2% per jaar.

Belangrijke informatie

58.87%

Groei van de winst

59.71%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.95%
Inkomstengroei18.24%
Rendement op eigen vermogen0.45%
Nettomarge-1.14%
Laatste winstupdate31 Mar 2026

Recente prestatie-updates uit het verleden

Recent updates

Seeking Alpha • May 13

Cronos: Excellent M&A And Favorable Valuation Make This A Buy (Upgrade)

Summary Cronos Group Inc. reported Q1 '26 revenue up 40% to $45 million, exceeding estimates. Despite strong top-line growth, CRON posted a small operating loss of $1.8 million, with net income driven by interest and FX gains. CapEx dropped sharply by 87% year-over-year to $1.9 million, reflecting tighter capital discipline. The acquisition of CanAdelaar will be a game changer for the company's European expansion, as it is extremely strong in both sales and production. Read the full article on Seeking Alpha
Seeking Alpha • Mar 06

Cronos Reports Improved Q4-2024 Financials With Revenues From GrowCo

Summary Cronos reported 27% increase in revenues YOY for Q4-2024. The company is now reporting revenues from its 50% ownership of GrowCo. The company reported increasing profits and free cash flow for the quarter. Cronos’ stock price is up 4.6% over the last twelve months. I rate the company as a Hold for now due to sector weakness. Read the full article on Seeking Alpha
Seeking Alpha • Dec 05

Cronos Group Is Probably Undervalued As Liquidity Swells

Summary CRON's financials show strong liquidity with a sequential increase in cash and cash equivalents, no debt, and positive free cash flow. Despite unprofitability, CRON's assets dwarf liabilities, and it trades at a price-to-book value of 0.71x. CRON's fiscal 2024 third-quarter revenue growth was driven by a 38.1% revenue increase and expanding international operations. The stock's near-term performance hinges on pending cannabis policy changes. Read the full article on Seeking Alpha
Seeking Alpha • Aug 20

Buy Cronos Stock Before It Surges Higher

Summary Initiating coverage on Cronos stock with a "Strong Buy" rating. Cannabis industry tailwinds, conservative growth approach, and geographic expansion support Cronos' growth acceleration and EBITDA margin improvement. A strong cash buffer of $848 million coupled with a zero-debt balance sheet provides flexibility for organic and acquisition-driven growth. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Cronos Group: An Intriguing Value Opportunity

Summary Cronos Group Inc. operates in Canada's recreational market and focuses on medicinal cannabis in lucrative markets like Germany and the U.K. The company is experiencing rapid revenue growth in Canada and Israel, with plans to enter new markets in the near future. Despite facing risks related to regulations and profitability, Cronos Group's low valuation makes it an attractive investment opportunity for long-term growth. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Cronos Stock: Attractive Now With Cannabis Legalization In Germany

Summary Cronos Group's Q4 and FY23 results were disappointing, with missed earnings and revenue targets. Cronos has a strong cash position and potential for cost savings, but has yet to decide how to allocate its funds. The German market could be an important growth engine for CRON and contribute to exceeding estimates. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Cronos Group: Flush With Cash And Trading Below Book Value

Summary Cronos Group has a cash position of $840 million, which is over 100% of its market cap, and zero debt. The company is trading at a discount to book value, with a potential 36% upside if the stock trades in line with book value. Cronos Group's operational losses are a factor in the current discount, but the company has seen improvements in revenue and gross profit. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Cronos Group press release (NASDAQ:CRON): Q2 GAAP EPS of -$0.05 beats by $0.01. Revenue of $23.1M (+47.9% Y/Y) misses by $5.25M. The increase year-over-year was primarily driven by an increase in net revenue in the Rest of World (“ROW”) segment driven by growth in the Israeli medical market and the Canadian adult-use market. Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022. Shares -2% PM.
Seeking Alpha • Aug 01

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Cronos was the first "pot stock" to list on the Nasdaq. The company has a strong cash position of ~$1bn, but losses in FY21 were $395m. Net loss in Q122 was a more modest $32.6m, while revenues were $25m. The issue is that Cronos has few options to deploy funds successfully in a market that remains largely on hold owing to US reluctance to legalise marijuana at the federal level. As such, I can see Cronos' market cap valuation shrinking at the same pace as its funds. Meanwhile, lead investor Altria could exercise an option and increase its ownership >50%. Investment Thesis Most listed companies involved in the business of cannabis cultivation and distribution, whether for recreational or medicinal purposes, trading on the Nasdaq, have seen their share prices nosedive over the past 12 months, and Cronos Group (CRON) is no exception. The Toronto, Canada based company was the first "Pot Stock" to uplist from the Toronto stock exchange (TSX) to the Nasdaq, in March 2018. Early investors would have been delighted with the initial rise in the company' stock price, from ~$7 shortly after the uplisting, to a "high" of nearly $22 in February 2019, but sadly, the gains were short-lived. Barring a brief spike to $10 in January 2021, it has been all downhill for the stock price, which currently trades at a value of $3.15 - down 58% across the past 12 months. Share price performance of Canadian Cannabis companies - past 12 months. (TradingView) As we can see below, rival Canada based cannabis stocks Tilray (TLRY), SNDL (SNDL), Aurora Cannabis (ACB), and Canopy Growth (CGC) have fared even worse. Of these companies, Aurora and Sundial Growers are relative minnow, with market caps of $320m and $535m respectively, Canopy Growth and Cronos are both valued ~$1.2bn, and Tilray is the largest, with a market cap of $1.6bn. Whilst Cronos, Canopy and Tilray boast impressively high cash positions of ~$1bn, $1.4bn, and $803m, the trouble is the companies are reluctant to deploy capital when the market opportunity is so small, and that is chiefly down to the US' refusal to legalise marijuana at the Federal level. A statement in Cronos 2021 10-K submission to the SEC explains: Though a number of states in the U.S. have authorized the cultivation, distribution or possession of U.S. Schedule I cannabis and U.S. Schedule I cannabis containing products to various degrees and subject to various requirements or conditions, U.S. Schedule I cannabis continues to be a Schedule I controlled substance under the CSA. Therefore, the cultivation, manufacture, distribution and possession of U.S. Schedule I cannabis violates federal law in the U.S. unless a U.S. federal agency, such as the DEA, grants a registration for a specific activity, such as research, with U.S. Schedule I cannabis. Cronos Group's Portfolio of Brands. (Cronos investor presentation) The US does permit trade in hemp related products, and as we can see above, Cronos is able to sell its Spinach cannabis brand in Canada, for mainstream adult use thanks to Canada's legalisation of marijuana, and also sells cannabis products for "Wellness" i.e. medicinal use in Australia, Canada, Germany and Israel, and 2 hemp-derived product portfolios in the US, under the Lord Jones and Happy Dance brands. These products don't generate strong revenue streams however - Cronos earned just $25m of revenues in Q122 - which is admittedly up 123% year-on-year - but posted a loss of $32.6m, and earned just $2.3m of revenues from the US. In FY21, 3 major customers - Ontario Cannabis Retail Corporation, Société Québécoise du Cannabis (the "SQDC"), and Alberta Gaming, Liquor and Cannabis Commission - accounted for 26%, 15%, and 15% of the company's revenues of $74.4m. The company's net loss in 2021 was $395.6m. With >600 employees on its payroll, and markets stubbornly refusing to open up, with only limited opportunities internationally in countries authorising cannabis for medicinal use, it's easy to make the bear case for Cronos, given its funds look likely to be exhausted by the end of 2023 at the current burn rate. The only thing likely to save the company is if the US legalises marijuana at the federal level - it is already decriminalised, but that is of no use to companies attempting to ship a schedule I product - defined by the FDA and DEA as having "no therapeutic value" meaning it "therefore cannot be lawfully possessed or prescribed". With all that said, however, in the event that the US does change the classification of marijuana, shareholders in companies like Cronos are likely to realise substantial triple digit gains, positioned as they are to capitalise on any positive developments, and these companies are trading at historical lows. In the rest of this post, I will take a closer look at the situation that Cronos currently finds itself in, and try to discuss whether there is a rewarding opportunity in investing in Cronos stock at a historically low price. Recent Developments in US There are many and persuasive reasons why the US may want to decriminalise cannabis, and these were discussed at a Senate Judiciary Committee Subcommittee on Criminal Justice and Counterterrorism hearing as recently as last week. The Cannabis Administration and Opportunity Act was also introduced by Senate Majority Leader Chuck Schumer last week, which, if passed, would deschedule marijuana as a Schedule I controlled substance. Senator Cory Booker chaired the discussion, highlighting issues such as social injustice, and the amount of police time that may be wasted on hunting down cannabis smokers - he told the senate that in 2019, there were more arrests for cannabis than for all violent crimes combined. Booker also noted that 91% of Americans are in favour of medical marijuana, and 68% support adult use. Despite some persuasive arguments, the "COAC" is unlikely to become because, apparently, it is viewed as too far reaching, and faces strong Republican opposition, whilst President Biden is not thought to favour legalisation at the federal level, preferring an "incremental" approach. The COAC certainly seems to represent praiseworthy progress, but it would be a stretch to claim that it is going to benefit a company like Cronos, firstly because it is unlikely to be passed, and secondly because its main thrust is towards providing social justice, rather than commercial opportunities. COAC may represent progress, but probably not fast enough to stem the flow of losses at Cronos. The Altria Question Meanwhile, Cronos reveals in its 2021 10-K submission that it is ~42% owned by Altria (MO), which made a $1.8bn investment into Cronos back in 2018. Altria is a $79bn market cap holding company, which engages in the manufacture and sale of cigarettes in the United States, and clearly the company saw an opportunity in the cannabis market that it sought to exploit by investing in Cronos. Altria also has the option to increase its stake in Cronos above 50%, at which point the company would effectively own Cronos and have the right to appoint an entirely new board, sell the business, or sell a significant amount of its shares in Cronos, resulting in further share price losses or issue more shares, resulting in investor dilution. Altria and Cronos initially felt there may have been an opportunity in the cannabis vaping market, but no such opportunity has arisen (to the best of my knowledge) and it's tempting to wonder if the much larger Altria intends to cut its losses in Cronos. As such, investors believing that it is only a matter of time before Cronos is in a position to exploit changes in cannabis legislation may be disappointed. Conclusion - Cronos' Bet On Cannabis Markets May Have Come Too Early Cronos' current business would actually look reasonably well organised and successful, based on its differentiated product offering, tailored to suit different markets, most notably Israel and Canada, were it not for the outrageous - for a company of its size - cash burn and meagre return of just $25m in Q122.
Seeking Alpha • May 11

Cronos Group: High Hurdles

Cronos Group is starting to make progress towards building a business warranting the original big Altria investment. The company is still reporting massive EBITDA losses for a business with quarterly revenues of just $25 million. The stock isn't appealing until Cronos leaps the large loss hurdle and finally invests the $1 billion cash balance in productive cannabis assets.
Seeking Alpha • Mar 01

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

After a long delay, Cronos releases both its third quarter and fourth quarter earnings results. Cronos Group's revenues grew 51%, but the adjusted EBITDA loss was more than revenues. Cronos is investing heavily in R&D, specifically, using synthetic biology to produce expensive cannabinoid compounds. CRON stock trades at a premium to Canadian peers, but that looks justified on account of the more rapid growth rate.
Seeking Alpha • Feb 22

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Cronos Group delayed filing of Q3-2021 earnings due to a revision and audit of Q2 reports. Cronos Group beat revenue (+$2.212 million) and EPS (+0.32) consensus on its Q3-2021 report. Revenues are increasing Cronos Group and it currently has synthetic cannabinoid products to market. CRON stock has been on a downtrend along with other cannabis stocks. I rate CRON as a hold and recommend investors watch for a new cannabis stock rally to emerge.
Seeking Alpha • Jan 22

Cronos Group: Still No Reason To Own

Cronos Group still hasn't launched a meaningful business. The Canadian cannabis LP still hasn't filed Q3'21 results. The stock isn't even investable with a $1.1 billion cash position due to massive ongoing EBITDA losses.
Seeking Alpha • Nov 08

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

Altria owns 42% of Cronos Group. Its warrants to take a majority stake are way out of the money and approaching expiration in early 2023. Cronos Group has an enterprise value of just $900 million and would not have a material impact on Altria's financials. Buying the balance of Cronos Group would fit strategically with Altria. The lack of a scheduled conference call ahead of a filing deadline for Q3 financials points to a potential imminent bid.
Seeking Alpha • Aug 30

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

CRON is a Canadian licensed producer of cannabis. How much did it pay for PharmaCann? I give my estimate for the valuation that it paid for its investment in the US cannabis operator PharmaCann. CRON trades at a huge premium to Canadian peers like Canopy Growth and Tilray, but I explain why the premium may be warranted. Would Altria still invest in CRON if it made its investment today? I analyze the company's financials and investment prospects as compared to US peers.
Seeking Alpha • Jul 12

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Cronos has taken a "slow and steady wins the race" approach to cannabis, with an obvious eye on a fully legalized American market. The case is slowly (and unevenly) playing out, with fermentation efforts progressing and the PharmaCann deal providing a first step into the U.S. At $8, CRON still looks attractive from a long-term perspective, but a key word there is "long-term."

Opbrengsten en kosten

Hoe Cronos Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:CRON Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Mar 26160-2725
31 Dec 25147-9694
30 Sep 2513236714
30 Jun 2513018744
31 Mar 2512549764
31 Dec 2411841764
30 Sep 24111-48745
30 Jun 24102-57755
31 Mar 2493-54775
31 Dec 2387-70816
30 Sep 2385-101877
30 Jun 2381-133918
31 Mar 2384-1459311
31 Dec 2287-15510113
30 Sep 2291-21310917
30 Jun 2291-10213021
31 Mar 2285-26314522
31 Dec 2165-12712222
30 Sep 2166-37315424
30 Jun 2157-38114222
31 Mar 2151-31013221
31 Dec 2047-7213020
30 Sep 203710112619
30 Jun 203163611617
31 Mar 202992910716
31 Dec 19241,16711612
30 Sep 19211,089658
30 Jun 1918479465
31 Mar 1913293323
31 Dec 1812-21242
30 Sep 189-8150
30 Jun 187-1110
31 Mar 185-290
31 Dec 173-170
30 Sep 174160
30 Jun 172050
31 Mar 171-140
31 Dec 160-130
30 Sep 162020
30 Jun 162010
31 Mar 163110
31 Dec 152010
30 Sep 150-420
30 Jun 15-1-420

Kwaliteitswinsten: CRON is momenteel verliesgevend.

Groeiende winstmarge: CRON is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CRON is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 58.9% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CRON over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CRON is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -5% ).

Rendement op eigen vermogen

Hoge ROE: CRON heeft een negatief Return on Equity ( 0.45% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/19 17:45
Aandelenkoers aan het einde van de dag2026/05/19 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cronos Group Inc. wordt gevolgd door 16 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein